))
Are CROs Losing Relevance in the Age of DCTs?
Manage episode 446551801 series 3506216
Contenido proporcionado por Darshan Kulkarni. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Darshan Kulkarni o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.
In this episode, Isaac Rodriguez- Chavez and I discuss the impact of DCTs on sponsor relationships, CROs, and industry dynamics with the FDA.
We discuss,
1. How will DCTs impact sponsor relationships with CROs?
2. How do small CROs and sponsors adapt to emerging trends?
3. How do new trends impact industry relationships with the FDA?
4. Does DCT allows the FDA to advise sponsors?
5. What is the role of technology in DCTs?
6. How do DCTs reduce the cost of bringing drugs to the market?
7. What are the risks and advantages of DCTs?
8. What are the initial risks of DCTs?
9. Does the FDA even have jurisdiction over patient privacy?
189 episodios
Compartir
